US2011152231A1PendingUtilityA1

Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms

48
Assignee: BENJAMIN RODNEYPriority: Oct 30, 2009Filed: Oct 29, 2010Published: Jun 23, 2011
Est. expiryOct 30, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Rodney BenjaminAnthony KellerJeffrey Varelman
A61P 31/10A61P 31/00A61P 43/00A61P 31/16A61P 31/04C12N 1/38A61K 45/06C12P 7/06A61K 31/437A61K 9/0014A61K 31/10C12P 7/56A01N 41/10C12N 1/20A61K 31/43C12N 1/18A61K 31/431Y02E50/10Y02A50/30Y02E50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.

Claims

exact text as granted — not AI-modified
1 . A method of inhibiting a drug resistant bacterial pathogen, comprising:
 selecting a drug resistant bacterial pathogen; and   contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive form of the drug resistant bacterial pathogen, thereby inhibiting a drug resistant bacterial pathogen.   
     
     
         2 . The method of  claim 1 , wherein the bacterial pathogen is MRSA. 
     
     
         3 . The method of  claim 1 , wherein the agent is a Beta-lactam antibiotic. 
     
     
         4 . The method of  claim 3 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof. 
     
     
         5 . The method of  claim 3 , wherein the agent comprises methicillin, oxacillin or penicillin. 
     
     
         6 . The method of  claim 1 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM. 
     
     
         7 . The method of  claim 1 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM. 
     
     
         8 . The method of  claim 1 , wherein the effective amount of MSM is about 10-16% MSM. 
     
     
         9 . The method of  claim 1 , wherein the bacterial pathogen is on a surface. 
     
     
         10 . The method of  claim 1 , wherein the bacterial pathogen is in a subject. 
     
     
         11 . The method of  claim 1 , wherein the composition is administered topically. 
     
     
         12 . The method of  claim 1 , wherein the composition is administered with an inhalant device. 
     
     
         13 . The method of  claim 1 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours. 
     
     
         14 . The method of  claim 1 , wherein the composition comprises 0-5% sodium chloride. 
     
     
         15 . A method of sensitizing a drug resistant bacterial pathogen to a drug the bacterial pathogen is resistant to, comprising
 selecting a drug resistant bacterial pathogen; and   contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM, thereby sensitizing the drug resistant bacterial pathogen to the drug the bacterial pathogen is resistant to.   
     
     
         16 . The method of  claim 15 , wherein the bacterial pathogen is MRSA. 
     
     
         17 . The method of  claim 15 , wherein the agent is a Beta-lactam antibiotic. 
     
     
         18 . The method of  claim 17 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof. 
     
     
         19 . The method of  claim 17 , wherein the agent comprises methicillin, oxacillin or penicillin. 
     
     
         20 . The method of  claim 15 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM. 
     
     
         21 . The method of  claim 15 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM. 
     
     
         22 . The method of  claim 15 , wherein the effective amount of MSM is about 10-16% MSM. 
     
     
         23 . The method of  claim 15 , wherein the bacterial pathogen is on a surface. 
     
     
         24 . The method of  claim 15 , wherein the bacterial pathogen is in a subject. 
     
     
         25 . The method of  claim 15 , wherein the composition is administered topically. 
     
     
         26 . The method of  claim 15 , wherein the composition is administered with an inhalant device. 
     
     
         27 . The method of  claim 15 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours. 
     
     
         28 . The method of  claim 15 , wherein the composition comprises 0-5% sodium chloride. 
     
     
         29 . A method of inhibiting a drug-sensitive bacterial pathogen from developing drug resistance, comprising:
 selecting a drug sensitive bacterial pathogen; and   contacting the drug-sensitive bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive bacterial pathogen, thereby inhibiting the drug-sensitive bacterial pathogen from developing drug resistance.   
     
     
         30 . The method of  claim 29 , wherein the bacterial pathogen is  Staphylococcus aureus.    
     
     
         31 . The method of  claim 29 , wherein the agent is a Beta-lactam antibiotic. 
     
     
         32 . The method of  claim 31 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof. 
     
     
         33 . The method of  claim 31 , wherein the agent comprises methicillin, oxacillin or penicillin. 
     
     
         34 . The method of  claim 29 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM. 
     
     
         35 . The method of  claim 29 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM. 
     
     
         36 . The method of  claim 29 , wherein the effective amount of MSM is about 10-16% MSM. 
     
     
         37 . The method of  claim 29 , wherein the bacterial pathogen is on a surface. 
     
     
         38 . The method of  claim 29 , wherein the bacterial pathogen is in a subject. 
     
     
         39 . The method of  claim 29 , wherein the composition is administered topically. 
     
     
         40 . The method of  claim 29 , wherein the composition is administered with an inhalant device. 
     
     
         41 . The method of  claim 29 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours. 
     
     
         42 . The method of  claim 29 , wherein the composition comprises 0-5% sodium chloride.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.